Adebowale Adeniran, MD
Professor of PathologyCards
Additional Titles
Director of Cytopathology
Director, Cytology Laboratory
Director, Cytopathology Fellowship Program, Pathology
Director, Anatomic Pathology Elective Program, Pathology
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director of Cytopathology
Director, Cytology Laboratory
Director, Cytopathology Fellowship Program, Pathology
Director, Anatomic Pathology Elective Program, Pathology
Contact Info
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileAdditional Titles
Director of Cytopathology
Director, Cytology Laboratory
Director, Cytopathology Fellowship Program, Pathology
Director, Anatomic Pathology Elective Program, Pathology
Contact Info
About
Titles
Professor of Pathology
Director of Cytopathology; Director, Cytology Laboratory; Director, Cytopathology Fellowship Program, Pathology; Director, Anatomic Pathology Elective Program, Pathology
Biography
Dr. Adebowale Adeniran is an experienced surgical pathologist and cytopathologist, and currently Director of Cytopathology and the Cytology Laboratory and Director of Cytopathology Fellowship Program. Dr. Adeniran obtained his MD degree from the University of Ibadan, Nigeria. He did his anatomic/clinical pathology residency at the University of Cincinnati Medical Center, followed by surgical pathology fellowship (with special interest in genitourinary pathology) at the University of Texas M.D. Anderson Cancer Center and cytopathology fellowship at the Memorial Sloan-Kettering Cancer Center. Dr. Adeniran is a practicing surgical and cyto pathologist, with a research focus on clinico-pathologic and molecular pathologic aspects of kidney cancer as well as thyroid cancer. He is an editorial board member of Cancer Cytopathology and Journal of Clinical and Translational Pathology, and a reviewer of several peer-reviewed journals. He has authored more than 130 manuscripts and book chapters, and co-authored two textbooks - Common Diagnostic Pitfalls in Thyroid Cytopathology and Rapid On-site Evaluation (ROSE): A Practical Guide. He currently serves as a member of the education committee of the United States and Canadian Academy of Pathology.
Appointments
Other Departments & Organizations
Education & Training
- Fellow
- Memorial Sloan Kettering Cancer Center (2008)
- Fellow
- M.D. Anderson Cancer Center (2007)
- Resident
- University of Cincinnati Medical Center (2006)
- MD
- University of Ibadan (1995)
Research
Overview
Biology of translocation renal cell carcinoma; Biology of the papillary thyroid carcinoma
Medical Research Interests
ORCID
0000-0001-9820-632X
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Harriet Kluger, MD
Guoping Cai, MD, MS
Michael Hurwitz, MD, PhD
Peter A Humphrey, MD, PhD
David A. Braun, MD, PhD
David Schoenfeld, MD, PhD
Carcinoma, Renal Cell
Kidney Neoplasms
Publications
2024
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma
Barata P, Tangen C, Plets M, Thompson I, Narayan V, George D, Heng D, Shuch B, Stein M, Gulati S, Tretiakova M, Tripathi A, Bjarnason G, Humphrey P, Adeniran A, Vaishampayan U, Alva A, Zhang T, Cole S, Lara P, Lerner S, Balzer-Haas N, Pal S. Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma. Journal Of Clinical Oncology 2024, 42: 3911-3916. PMID: 39255440, PMCID: PMC11575905, DOI: 10.1200/jco.24.00767.Peer-Reviewed Original ResearchConceptsAdvanced papillary renal cell carcinomaPapillary renal cell carcinomaRenal cell carcinomaOverall survivalCell carcinomaProlonged progression-free survivalLack of survival benefitProgression-free survivalRandomized phase IIMedian follow-upPrimary end pointOpen-label trialOverall survival analysisCrizotinib armMedian OSSurvival benefitClinical trial updateNo significant differenceCabozantinibTreatment armsSunitinibFollow-upClinical trialsSavolitinibCrizotinibEvaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series
Rahman S, Kong V, Jalfon M, Hesse D, Kim J, Wright J, Adeniran A, Humphrey P, Martin D, Ghali F. Evaluating Treatment Patterns and the Role of Neoadjuvant Chemotherapy in Plasmacytoid Urothelial Carcinoma: Insights from a Combined National and Institutional Series. Cancers 2024, 16: 3050. PMID: 39272908, PMCID: PMC11394101, DOI: 10.3390/cancers16173050.Peer-Reviewed Original ResearchConceptsPlasmacytoid urothelial carcinomaMedian overall survivalNeoadjuvant chemotherapyUrothelial carcinomaOverall survivalTreatment patternsReceipt of neoadjuvant chemotherapyResponse to current therapiesCharacterize treatment patternsCox proportional hazards analysisEvaluate treatment patternsSite of metastasisProportional hazards analysisPT0 rateOS benefitHistological subtypesClinical stageCurrent therapiesInstitutional experiencePrimary outcomeNCDBTreatment trendsEffective treatmentPatientsCarcinomaGP100 expression is variable in intensity in melanoma
Mann J, Hasson N, Su D, Adeniran A, Smalley K, Djureinovic D, Jilaveanu L, Schoenfeld D, Kluger H. GP100 expression is variable in intensity in melanoma. Cancer Immunology, Immunotherapy 2024, 73: 191. PMID: 39105816, PMCID: PMC11303354, DOI: 10.1007/s00262-024-03776-5.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsGp100 expressionCutaneous melanomaTreatment of cutaneous melanomaAdvanced cutaneous melanomaT-cell engagersImprove patient selectionMetastatic melanomaUveal melanomaMetastatic samplesPatient selectionClinical trialsMelanomaQuantitative immunofluorescence methodGp100Improve outcomesImmunofluorescence methodTherapeutic intentDrugCellular productsExpressionTebentafuspImmunohistochemistryTIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3
Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, Kluger H, Schoenfeld D. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology, Immunotherapy 2024, 73: 192. PMID: 39105820, PMCID: PMC11303630, DOI: 10.1007/s00262-024-03773-8.Peer-Reviewed Original ResearchMeSH Keywords and ConceptsConceptsRenal cell carcinomaRenal cell carcinoma tumorsT cellsTIGIT expressionCheckpoint inhibitorsPD-1Likelihood of response to therapyTumor-infiltrating T cellsCD3+ T cellsRenal cell carcinoma metastasisTreatment of renal cell carcinomaImmune checkpoint inhibitorsInfiltrating T cellsPurposeImmune checkpoint inhibitorsResponse to therapyT cell immunoglobulinCD3+ levelsMetastatic RCC specimensAdjacent normal renal tissuesNormal renal tissuesQuantitative immunofluorescence analysisCell carcinomaResistant diseasePotential therapeutic targetTissue microarrayDevelopment of anex vivo patient-derived tumor model (PDTM) to assess the tumor microenvironment in renal cell carcinoma (RCC)
Kashima S, Gupta R, Moritz V, Sadak K, Adeniran A, Humphrey P, Dinulescu D, Palmer D, Hammond S, Bosenberg M, Hurwitz M, Kenney P, Braun D. Development of anex vivo patient-derived tumor model (PDTM) to assess the tumor microenvironment in renal cell carcinoma (RCC). The Oncologist 2024, 29: s5-s6. PMCID: PMC11301923, DOI: 10.1093/oncolo/oyae181.008.Peer-Reviewed Original ResearchConceptsRCC tumor microenvironmentPatient-derived tumor modelsRenal cell carcinomaImmune checkpoint inhibitorsT cell functionPeripheral blood mononuclear cellsEnzyme-linked immunosorbent assayTumor microenvironmentT cellsFlow cytometryTumor fragmentsIFN-gTumor modelTumor samplesCytokine productionHealthy donor peripheral blood mononuclear cellsImpact of immune checkpoint inhibitorsAnti-PD-1 monoclonal antibodyDonor peripheral blood mononuclear cellsCD4+CD25+ regulatory T cellsCD8+ T cell populationsResection of renal cell carcinomaSurgical resection of renal cell carcinomaAnti-PD-1 antibodyMetastatic renal cell carcinomaPathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma
Tripathi A, Tangen C, Plets M, Li X, Tretiakova M, Humphrey P, Adeniran A, Barata P, Gulati S, Bergerot C, Pruthi D, Thompson I, Lara P, Lerner S, Pal S, Shuch B. Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU International 2024, 134: 596-601. PMID: 39014969, DOI: 10.1111/bju.16403.Peer-Reviewed Original ResearchConceptsPapillary renal cell carcinomaPositive predictive valueRenal cell carcinomaLocal pathology reviewCentral reviewPathology reviewCell carcinomaAdvanced papillary renal cell carcinomaMetastatic papillary renal cell carcinomaPapillary renal cell carcinoma subtypesPatients treated with targeted therapyExpert genitourinary pathologistsPathological concordance rateLocal reviewGenitourinary pathologistsClinical benefitCabozantinibClinical significanceClinical valueSubtype assignmentConcordance rateType 1CarcinomaPatientsPredictive valueCytomorphological characteristics of low‐grade papillary urothelial carcinoma in voided urine samples: Distinction from benign and high‐grade papillary urothelial carcinoma
Takeda K, Adeniran A, Levi A, Tang H, Cai G. Cytomorphological characteristics of low‐grade papillary urothelial carcinoma in voided urine samples: Distinction from benign and high‐grade papillary urothelial carcinoma. Cytopathology 2024, 35: 724-732. PMID: 38992916, DOI: 10.1111/cyt.13413.Peer-Reviewed Original ResearchConceptsHigh-grade papillary urothelial carcinomaLow-grade papillary urothelial carcinomaPapillary urothelial carcinomaUrothelial carcinomaVoided urine samplesCytomorphologic featuresBenign casesUrine samplesUrine specimensNuclear enlargementVoided urine specimensHigh-grade transformationNuclear-to-cytoplasmic (N/CIrregular nuclear membranesUrine cytologyRetrospective reviewHistopathological diagnosisCytomorphologic characteristicsCytomorphological distinctionFrequent recurrenceCytologic featuresCarcinomaBenign conditionsAccurate diagnosisHigh N/C ratioReevaluation of ovarian cyst fine-needle aspiration cytology: A 10-year institutional experience
Takeda K, Cai G, Adeniran A, Sun T. Reevaluation of ovarian cyst fine-needle aspiration cytology: A 10-year institutional experience. American Journal Of Clinical Pathology 2024, aqae077. PMID: 38916141, DOI: 10.1093/ajcp/aqae077.Peer-Reviewed Original ResearchConceptsCystic fluid cytologyFine-needle aspirationFluid cytologyAmerican College of Obstetricians and Gynecologists guidelinesSingle-institution cohortRate of malignancySurgical pathology diagnosisFNA casesGynecologists guidelinesCytological diagnosisFNA cytologyPathological diagnosisPatient demographicsInstitutional experienceSurgical pathologyOvarian cyst fluidClinical circumstancesAmerican CollegeCytologyRadiological informationMalignancyGold standardCyst fluidModerate sensitivityPotential safety concernsSarcomatoid and Rhabdoid Renal Cell Carcinoma
Adeniran A, Shuch B, Humphrey P. Sarcomatoid and Rhabdoid Renal Cell Carcinoma. The American Journal Of Surgical Pathology 2024, 48: e65-e88. PMID: 38736105, DOI: 10.1097/pas.0000000000002233.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaSarcomatoid renal cell carcinomaGenomic alterationsRhabdoid differentiationRhabdoid cellsCell carcinomaWHO classification of renal tumorsClassification of renal tumorsInternational Collaboration on Cancer ReportingHistologic types of renal cell carcinomaPleomorphic undifferentiated sarcomaMalignant spindle cellsAggressive biological behaviorMolecular featuresMolecular mechanisms of tumorigenesisMechanisms of tumorigenesisSarcomatoid growthRhabdoid componentSarcomatoid componentRhabdoid featuresRenal tumorsClinical responseCollege of American PathologistsRhabdoid morphologySarcomatoid elements
2023
Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐up
Khajir G, Sun T, Wang H, Sprenkle P, Adeniran A, Cai G, Levi A. Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow‐up. Cytopathology 2023, 35: 235-241. PMID: 37916579, DOI: 10.1111/cyt.13328.Peer-Reviewed Original ResearchConceptsHigh-grade urothelial carcinomaLow-grade urothelial carcinomaUpper urinary tractUrothelial carcinomaUrinary tractCytologic evaluationCytology specimensInstitutional retrospective studyParis SystemHigh-grade malignancyAtypical urothelial cellsCytologic categoriesRetrospective studyInstitutional databaseCytological diagnosisUrinary cytopathologyHistopathologicMalignant cellsBenign casesUrothelial cellsTPS categoryCarcinomaReporting systemTractAUC
Academic Achievements & Community Involvement
activity Education Committee, United States and Canadian Academy of Pathology
Professional OrganizationsCommittee MemberDetails2021 - Presentactivity CheckPath Clinical Pathology Committee, American Society for Clinical Pathology
Professional OrganizationsCommittee MemberDetails2018 - Presentactivity International Accreditation Committee, College of American Pathologists
Professional OrganizationsCommittee MemberDetails2022 - Presentactivity Clinical Practice Committee, American Society of Cytopathology
Professional OrganizationsCommittee MemberDetails2020 - Presentactivity Tissue Committee, Yale New Haven Hospital
CommitteesCo-ChairDetails2018 - Present
Clinical Care
Overview
Adebowale Adeniran, MD, is a pathologist who specializes in diagnosing diseases of the genitourinary system (reproductive and urinary organs). He identifies kidney, prostate, and bladder cancers from patients’ biopsies. Dr. Adeniran also specializes in diagnosing thyroid diseases and cancer.
“The principal role of the pathologist is to provide an accurate diagnosis of a patient’s condition, which allows the physician to refine treatment options,” he says. “Pathologists and physicians work together to toward providing the best patient care.”
Dr. Adeniran decided to pursue pathology as a specialty during an academic fellowship at the University of Cincinnati Medical Center. “I saw the impact pathologists could have in terms treatment for patients by the diagnoses they made,” he says.
As director of the cytopathology and cytology labs at Yale School of Medicine, Dr. Adeniran oversees those daily operations and provides guidance to medical students and residents who are completing their training after medical school.
At the medical school, Dr. Adeniran is associate professor of pathology. In his research, he investigates the basic biology behind a cancer called papillary renal cell carcinoma and also works to better understand the molecular underpinnings of thyroid cancer.
Clinical Specialties
Board Certifications
Cytopathology
- Certification Organization
- AB of Pathology
- Latest Certification Date
- 2019
- Original Certification Date
- 2008
Anatomic & Clinical Pathology
- Certification Organization
- AB of Pathology
- Latest Certification Date
- 2018
- Original Certification Date
- 2007
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews & Links
News
- September 25, 2024
Pathology Team Encouraged About Migration to Epic Beaker Laboratory Information System
- December 19, 2023
Yale Pathologists Lead Effort to Revitalize Connecticut Society of Pathologists
- November 07, 2023
Yale Diagnostic Pathology Annual CME Review held in NYC
- July 18, 2023
New Funding to Support Kidney Cancer Research in Braun Lab
Related Links
Get In Touch
Contacts
Locations
Clinic Building
Academic Office
789 Howard Avenue, Ste CB 510A
New Haven, CT 06519
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.